← All Uniqure NV filings

Uniqure NV 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
QURE
Uniqure NV
10-K: uniQure Faces Regulatory Hurdle for Huntington's Gene Therapy
uniQure N.V. reported positive topline data for its lead Huntington's disease gene therapy, AMT-130, but the FDA deemed the current Phase I/II data insufficient for a Biologics License Application (BLA) submission, recommending a randomized, double-blind, sham surgery-controlled study.
NASDAQ
QURE
Uniqure NV
10-K: uniQure Reports 2024 Results, Outlines Path Forward for Gene Therapy Pipeline
uniQure N.V. details its 2024 financial results and provides updates on its gene therapy programs, including progress on AMT-130 for Huntington's disease and other clinical candidates.
NASDAQ
QURE
Uniqure NV
10-K: uniQure N.V. Outlines Capital Structure and Corporate Governance in SEC Filing
uniQure N.V. details its share structure, director duties, and shareholder rights under Dutch law, contrasting them with Delaware corporate law in a recent SEC filing.